Syntara (ASX:SNT) reported that it is developing a topical anti-fibrotic drug candidate, SNT-9465, as part of its expanded skin scarring program, according to a Tuesday Australian bourse filing.
The AU$2 million clinical development plan for SNT-9465, funded from existing cash reserves, is designed to demonstrate the drug's safety and tolerability as well as to study its ability to improve both the appearance and physical properties of hypertrophic scars.
A phase 1a dose escalation study in healthy volunteers will be conducted to determine the optimal dose for complete lysyl oxidase inhibition. This will be followed by an open-label phase 1b extension, which will assess improvements in the appearance and composition of hypertrophic scars that are less than 24 months old, after three months of daily treatment.
It expects the results to come in the first half of 2026.
Meanwhile, The Fiona Wood Foundation and the University of Western Australia will conduct an exploratory clinical trial on keloid scarring and Syntara will provide financial and technical support.
The firm's shares rose 3% in recent trading on Tuesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。